Document is current
Any future updates will be listed below
-
Authors
Yan, Mabel K. https://orcid.org/0000-0002-4700-3781
Cust, Anne E.
Soyer, H. Peter
Janda, Monika
Loewe, Katja
Byars, Gabrielle
Fishburn, Paul
White, Paul
Mahumud, Rashidul Alam
Saw, Robyn P. M.
Herschtal, Alan
Fernandez-Penas, Pablo
Guitera, Pascale
Morton, Rachael L.
Kelly, John
Wolfe, Rory
Mar, Victoria J.
-
Funding
Funding for this research was provided by:
Medical Research Future Fund - Targeted Health System and Community Organisation Research (RGMS ID: 1175082)
- License Information
-
More Information
Article History
Received: 20 March 2022
Accepted: 27 February 2023
First Online: 29 March 2023
Declarations
:
: The study has been reviewed and approved by Alfred Hospital Ethics Committee (HREC/59606/Alfred-2020). Written informed consent will be obtained from all recruited participants.
: The study results will be made available to participants and disseminated through peer-reviewed publications, conferences and media outlets. Participants are asked to provide optional consent to the use of their non-identifiable images for presentations and publications and/or the use of their images (including their face, but no other identifiable information) for further research.
: RPMS has received honoraria for advisory board participation from MSD, Novartis and Qbiotics and speaking honoraria from BMS and Novartis. HPS is a shareholder of MoleMap NZ Limited and e-derm consult GmbH and undertakes regular teledermatological reporting for both companies. HPS is a medical consultant for Canfield Scientific Inc., MoleMap Australia Pty Ltd., Blaze Bioscience Inc. and a Medical Advisor for First Derm. PG receives some honoraria from Metaoptima, CA.The other authors declare that they have no competing interests.
